MindWalk (HYFT) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MindWalk (HYFT) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 23.5% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -78.3% for HYFT. Oncolytics Biotech is the larger company by market cap ($71.1 million vs $69.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | ONCY |
|---|---|---|
| Share price | $1.48 | $0.5426 |
| Market cap | $69.76M | $71.15M |
| 1-day change | +3.55% | -0.33% |
| YTD return | -21.43% | -37.43% |
| 1-year return | -23.53% | -57.47% |
| 5-year return | -78.27% | -75.48% |
| EPS (TTM) | $-0.26 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.99 | $1.32 |
| 52-week low | $0.99 | $0.525 |
| Distance from 52-week high | -50.48% | -58.89% |
| Analyst consensus | none | buy |
| Avg. price target upside | +192.43% | +664.84% |
| Average volume | 229.74K | 1.08M |
| Shares outstanding | 47.11M | 131.12M |
| Employees | 74 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed ONCY by 33.9 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
HYFT vs ONCY FAQ
Which is bigger, MindWalk or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $71.15M compared with $69.76M for MindWalk (HYFT).
Which stock has performed better over the past year, HYFT or ONCY?
HYFT returned -23.53% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.